IL116511A0 - Mutant enzymes - Google Patents

Mutant enzymes

Info

Publication number
IL116511A0
IL116511A0 IL11651195A IL11651195A IL116511A0 IL 116511 A0 IL116511 A0 IL 116511A0 IL 11651195 A IL11651195 A IL 11651195A IL 11651195 A IL11651195 A IL 11651195A IL 116511 A0 IL116511 A0 IL 116511A0
Authority
IL
Israel
Prior art keywords
enzyme
host
prodrug
component
natural
Prior art date
Application number
IL11651195A
Other languages
English (en)
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116511(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL116511A0 publication Critical patent/IL116511A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
IL11651195A 1994-12-23 1995-12-22 Mutant enzymes IL116511A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds

Publications (1)

Publication Number Publication Date
IL116511A0 true IL116511A0 (en) 1996-07-23

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11651195A IL116511A0 (en) 1994-12-23 1995-12-22 Mutant enzymes

Country Status (23)

Country Link
US (1) US5985281A (da)
EP (1) EP0806964B1 (da)
JP (1) JP3805365B2 (da)
KR (1) KR100270650B1 (da)
CN (1) CN1095677C (da)
AT (1) ATE222124T1 (da)
AU (1) AU701916B2 (da)
BR (1) BR9510490B1 (da)
CA (1) CA2205091A1 (da)
CZ (1) CZ195297A3 (da)
DE (1) DE69527805T2 (da)
ES (1) ES2181805T3 (da)
FI (1) FI972683A0 (da)
HU (1) HUT77450A (da)
IL (1) IL116511A0 (da)
MX (1) MX9704575A (da)
NO (1) NO972882L (da)
NZ (1) NZ297529A (da)
PL (1) PL184031B1 (da)
RU (1) RU2189251C2 (da)
SK (1) SK80997A3 (da)
TR (1) TR199501654A2 (da)
WO (1) WO1996020011A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900062A3 (en) * 1995-08-16 1999-11-29 Zeneca Ltd Chemical compounds
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
ATE499115T1 (de) * 1998-09-18 2011-03-15 Immunomedics Inc Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
RU2002110121A (ru) * 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Слитые белки, полученные трансгенным способом
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA2506629A1 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
CN101511774B (zh) * 2006-10-03 2015-05-13 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
JP3273608B2 (ja) * 1989-01-23 2002-04-08 アクゾ・エヌ・ヴエー 治療薬の部位特異的インビボ活性化
JP3431146B2 (ja) * 1992-01-30 2003-07-28 ジェンザイム・リミテッド 改変した酵素によるキラル合成
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
TR199501654A3 (da) 1996-07-21
MX9704575A (es) 1997-10-31
JP3805365B2 (ja) 2006-08-02
FI972683L (fi) 1997-06-19
DE69527805D1 (de) 2002-09-19
US5985281A (en) 1999-11-16
AU701916B2 (en) 1999-02-11
EP0806964B1 (en) 2002-08-14
JPH10511547A (ja) 1998-11-10
FI972683A7 (fi) 1997-06-19
NO972882D0 (no) 1997-06-20
AU4269796A (en) 1996-07-19
CN1171054A (zh) 1998-01-21
BR9510490A (pt) 1998-01-13
CN1095677C (zh) 2002-12-11
SK80997A3 (en) 1998-02-04
RU2189251C2 (ru) 2002-09-20
EP0806964A1 (en) 1997-11-19
FI972683A0 (fi) 1997-06-19
HUT77450A (hu) 1998-04-28
BR9510490B1 (pt) 2010-10-05
CZ195297A3 (en) 1997-12-17
WO1996020011A1 (en) 1996-07-04
CA2205091A1 (en) 1996-07-04
DE69527805T2 (de) 2003-04-24
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
ATE222124T1 (de) 2002-08-15
PL184031B1 (pl) 2002-08-30
NZ297529A (en) 1999-07-29
ES2181805T3 (es) 2003-03-01
TR199501654A2 (tr) 1996-07-21
NO972882L (no) 1997-08-19

Similar Documents

Publication Publication Date Title
IL116511A0 (en) Mutant enzymes
AU7123296A (en) Liposomal formulations of mitoxantrone
IL105503A0 (en) Active compounds
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
BR9812079A (pt) Salmonella sp. mutante, lipopolissacarìdeo, processo para inibir o crescimento ou reduzir o volume de um câncer de tumor sólido, composição farmacêutica, e, processo aperfeiçoado para selecionar alterações genéticas em uma bactéria.
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
ZA988289B (en) Genetically modified tumor-targeted bacteria with reduced virulence
DE69435025D1 (de) Gangliosid-KLH-Konjugatimpfstoffe mit QS-21 zur Verzögerung des Wiederauftretens eines Melanoms
IL132348A0 (en) Gene directed antibody-enzyme prodrug therapy
EP0859625A4 (en) COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
MX9707944A (es) Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
AU1355697A (en) Allogeneic paracrine cytokine tumor vaccines
HUP0105208A2 (hu) Génterápiás alkalmazások
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
NZ326436A (en) Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors
GB2317387A (en) Chemical compounds
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
AU3991899A (en) Verotoxin b subunit for immunization
AU3796297A (en) Pituitary differentiation factor and methods of use thereof
WO2023212632A3 (en) Anti-nucleophosmin 1 antibody and antibody conjugate combination therapies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees